Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Privigen hemolysis antibody-binding study in chronic ITP
2011-000263-27Phase 4Completed
- Sponsor
- CSL Behring
- Start
- Jun 2011
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyvalent human immunoglobulin in immune thrombocytopenic purpura (ITP), sponsored by CSL Behring. Primary endpoint: Specificity of in vivo antibody binding to red blood cells. Started Jun 2011; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on 2011-000263-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000263-27.